These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7769797)

  • 1. Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans.
    MacFadyen RJ; Jones CR; Doig JK; Birnbock H; Reid JL
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):347-53. PubMed ID: 7769797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers.
    Doig JK; MacFadyen RJ; Sweet CS; Reid JL
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):511-7. PubMed ID: 7596116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man.
    Doig JK; MacFadyen RJ; Sweet CS; Lees KR; Reid JL
    J Cardiovasc Pharmacol; 1993 May; 21(5):732-8. PubMed ID: 7685442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
    Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
    Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
    Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
    Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
    Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
    Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men.
    McIntyre M; MacFadyen RJ; Meredith PA; Brouard R; Reid JL
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):101-6. PubMed ID: 8797143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.
    McIntyre M; MacFadyen RJ; Meredith PA; Menard J; Brunner HR; Insuasty J; Reid JL
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):994-1000. PubMed ID: 7564347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.
    Himmelmann A; Bergbrant A; Svensson A; Hansson L; Aurell M
    Am J Hypertens; 1996 Jun; 9(6):517-22. PubMed ID: 8783774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
    Burnier M; Rutschmann B; Nussberger J; Versaggi J; Shahinfar S; Waeber B; Brunner HR
    Hypertension; 1993 Sep; 22(3):339-47. PubMed ID: 8349327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
    Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
    Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms.
    Opsahl JA; Goldberg MR; Katz SA
    Am J Hypertens; 1995 Nov; 8(11):1090-8. PubMed ID: 8554732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
    J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
    Cockcroft JR; Sciberras DG; Goldberg MR; Ritter JM
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
    Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
    Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension.
    van Paassen P; de Zeeuw D; de Jong PE
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):39-45. PubMed ID: 7564363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
    Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
    Munafo A; Christen Y; Nussberger J; Shum LY; Borland RM; Lee RJ; Waeber B; Biollaz J; Brunner HR
    Clin Pharmacol Ther; 1992 May; 51(5):513-21. PubMed ID: 1587065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men.
    Doig JK; MacFadyen RJ; Meredith PA; Fischli W; Reid JL
    J Cardiovasc Pharmacol; 1992 Dec; 20(6):875-80. PubMed ID: 1282588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.